Target Name: RBAK-RBAKDN
NCBI ID: G100533952
Other Name(s): RB-associated KRAB repressor | Zinc finger protein 769 | RBAK-RBAKDN readthrough | ZNF769 | RBAK-LOC389458 readthrough | RB-associated KRAB zinc finger protein | RBAK | hRBaK | RBAK-LOC389458 | Protein RBAK-RBAKDN

RBAK-RBAKDN: A Promising Drug Target / Biomarker

RBAK-RBAKDN is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. Its full name is retinal-protein-associated kinase-related B-type DNA-binding protein. It is a potential drug target or biomarker that can be used for the treatment of various diseases, including neurodegenerative disorders, diabetes, and cancer.

The RBAK-RBAKDN Protein

RBAK-RBAKDN is a 21-kDa protein that is expressed in the brain and other tissues of the body. It is characterized by a N-terminal domain that contains a catalytic active site and a C-terminal domain that contains a nuclear localization region. The N-terminal domain contains a short amino acid sequence that is specific to RBAK-RBAKDN and is involved in the protein's nuclear localization. The C-terminal domain contains a long amino acid sequence that is involved in the protein's DNA-binding properties.

RBAK-RBAKDN's DNA-binding Properties

RBAK-RBAKDN is a DNA-binding protein that can interact with specific DNA sequences. Its DNA-binding properties are regulated by various factors, including its phosphorylation state and its presence in the form of a complex with DNA. RBAK-RBAKDN has been shown to play a role in the regulation of gene expression and has been linked to the development and progression of various diseases, including neurodegenerative disorders, diabetes, and cancer.

In Neurodegenerative Disorders

RBAK-RBAKDN has been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that RBAK-RBAKDN is expressed in the brains of individuals with these disorders and that its levels are decreased in the brains of individuals with these disorders compared to age-matched controls. Additionally, RBAK-RBAKDN has been shown to interact with other proteins that are involved in the development and progression of these disorders, including tau and beta-amyloid.

In Diabetes

RBAK-RBAKDN has also been shown to be involved in the development and progression of diabetes. Studies have shown that RBAK-RBAKDN is expressed in the pancreatic cells of individuals with type 1 diabetes and that its levels are decreased in these cells compared to the cells of individuals without diabetes. Additionally, RBAK-RBAKDN has been shown to interact with other proteins that are involved in the development and progression of diabetes, including Insulin-like growth factor 1 (IGF-1) and GLUT1.

In Cancer

RBAK-RBAKDN has also been shown to be involved in the development and progression of cancer. Studies have shown that RBAK-RBAKDN is expressed in various tissues of individuals with cancer and that its levels are often decreased in these tissues compared to the surrounding tissues. Additionally, RBAK-RBAKDN has been shown to interact with other proteins that are involved in the development and progression of cancer, including p53 and NF-kappa-B.

Potential Therapeutic Applications

Given RBAK-RBAKDN's involvement in the regulation of gene expression and its potential involvement in the development and progression of various diseases, there is a high demand for compounds that can inhibit its activity. Currently, there are several RBAK-RBAKDN inhibitors that are being developed as potential therapeutic compounds for the treatment of neurodegenerative disorders, diabetes, and cancer. These compounds can include small molecules, peptides, and proteins.

Conclusion

RBAK-RBAKDN is a protein that is expressed in various tissues

Protein Name: RBAK-RBAKDN Readthrough

More Common Targets

RBAKDN | RBBP4 | RBBP4P2 | RBBP4P6 | RBBP5 | RBBP6 | RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1